UPDATE 1-Paladin Labs' grass allergy drug gets Canadian nod
March 21 (Reuters) - Paladin Labs Inc said the Canadian health regulator approved its oral drug to treat seasonal grass allergies.
The Canadian specialty pharmaceutical company expects to launch the drug, Oralair, in 2013.
Paladin, which bowed out of bidding for Afexa -- maker of Canada's No. 1 selling cold and flu medicine Cold-FX -- said about 20 percent to 25 percent of adults in Canada have respiratory allergies and half of those would be grass pollen allergies.
Oralair, which can be taken at home, has been marketed in Europe since 2008.
Paladin obtained the Canadian development and marketing rights for Oralair from Stallergenes SA in January 2007.
Paladin shares closed at C$39.50 on Tuesday on the Toronto Stock Exchange.
- White House reverses, says Obama met uncle and lived with him during law school
- South Africa mourns Mandela, will bury him on December 15 |
- RPT-UPDATE 1-Ford leans on global Mustang to burnish overseas image
- Flights delayed as air pollution hits record in Shanghai
- U.S. television, Twitter, alive with new version of 'Sound of Music'